We are live on ! Find out more
WX

WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX

Delisted

WX was delisted on the 10th of December, 2015.

157 hedge funds and large institutions have $2B invested in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in 2014 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 65 increasing their positions, 42 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 42

16% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 19

2% more funds holding

Funds holding: 154157 (+3)

5% more capital invested

Capital invested by funds: $1.91B → $2B (+$90M)

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

45% less call options, than puts

Call options by funds: $1.31M | Put options by funds: $2.36M

Holders
157
Holders Change
+3
Holders Change %
+1.95%
% of All Funds
4.56%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.12%
New
22
Increased
65
Reduced
42
Closed
19
Calls
$1.31M
Puts
$2.36M
Net Calls
-$1.06M
Net Calls Change
-$3.01M
Name Holding Trade Value Shares
Change
Change in
Stake
LPL Financial
126
LPL Financial
California
$295K +$289K +8,442 New
JGUA
127
John G. Ullman & Associates
New York
$283K -$8.57K -250 -3%
NEI
128
Northwest & Ethical Investments
Ontario, Canada
$278K +$41.8K +1,220 +18%
OC
129
Oppenheimer & Co
New York
$272K
B
130
BancorpSouth
Mississippi
$272K +$23.9K +698 +10%
CAM
131
ClariVest Asset Management
California
$271K
Creative Planning
132
Creative Planning
Kansas
$270K -$142K -4,142 -35%
VKH
133
Virtu KCG Holdings
New York
$240K +$235K +6,857 New
Credit Agricole
134
Credit Agricole
France
$186K -$61.7K -1,800 -25%
AAM
135
Advisors Asset Management
Colorado
$175K +$9.8K +286 +6%
Citigroup
136
Citigroup
New York
$153K -$1.78K -52 -1%
US Bancorp
137
US Bancorp
Minnesota
$124K -$9.49K -277 -7%
Baillie Gifford & Co
138
Baillie Gifford & Co
United Kingdom
$85K +$83.4K +2,433 New
LTFS
139
Ladenburg Thalmann Financial Services
Florida
$65K +$9.67K +282 +18%
BC
140
Bartlett & Co
Ohio
$64K
DekaBank Deutsche Girozentrale
141
DekaBank Deutsche Girozentrale
Germany
$61K +$59.8K +1,745 New
ST
142
Smithfield Trust
Pennsylvania
$51K -$75.9K -2,215 -60%
S
143
SignatureFD
Georgia
$51K +$49.7K +1,450 New
AIG
144
American International Group
New York
$35K
Envestnet Asset Management
145
Envestnet Asset Management
Illinois
$29K -$17.8K -519 -39%
FHA
146
First Horizon Advisors
Tennessee
$25K +$2.91K +85 +13%
ACS
147
Archford Capital Strategies
Illinois
$22K
FNBT
148
FineMark National Bank & Trust
Florida
$19K
IRS
149
Invictus RG (Singapore)
Singapore
$18K +$17.1K +500 New
IMS
150
Index Management Solutions
Pennsylvania
$16K

WX Hedge Fund Activity: Q3 2014 in Review

157 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) for Q3 2014, worth a combined $2B — up 4.7% from $1.91B a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new WX positions and 19 closed out — a net gain of 3 holders — while 65 added to existing stakes and 42 trimmed.

The largest buyer was Fidelity International, adding an estimated $55.5M. The largest seller was Mirae Asset Global Investments, cutting an estimated $63.6M.

  • 157 institutional investors held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) as of Q3 2014, up from 154 in Q2 2014.
  • Funds reported $2B of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS stock for Q3 2014, up 4.7% quarter-over-quarter.
  • 22 funds opened new WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS positions in Q3 2014 and 19 closed out, a net change of +3 holders.
  • The largest WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS buyer in Q3 2014 was Fidelity International, an estimated $55.5M added.
  • The largest WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS seller in Q3 2014 was Mirae Asset Global Investments, an estimated $63.6M sold.

Based on aggregated 13F filings for Q3 2014.